Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust […]
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies […]
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) […]
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug […]
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding (MoU) with the International Olympic Committee (IOC) […]
As part of the Biden Administration’s ongoing efforts to promote health equity in response to the COVID-19 pandemic, the U.S. Department of Health and Human […]
HHS Office of Minority Health Will Offer Localities Funding to Partner with Community Organizations to Connect Minority, Underserved Populations with Vital Services, Promote Pandemic Safety […]
How to tell if a device is approved, cleared, or authorized by the FDA During the COVID-19 pandemic, some companies are selling medical devices (including […]
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that […]
Demonstrates Sera from Individuals Immunized with the Pfizer-BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations Pfizer Inc. (NYSE: PFE) and BioNTech SE […]
….in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants Pfizer Inc. (NYSE: PFE) […]
Copyright © 2021 | WordPress Theme by MH Themes
